IBA SA : IBA Strengthens Management Team for Future Growth
02 Juin 2016 - 7:00AM
IBA Strengthens
Management Team for Future Growth
Louvain-La-Neuve,
Belgium, 2 June 2016 - IBA (Ion Beam Applications S.A.,
EURONEXT), the world's leading provider of proton therapy solutions
for the treatment of cancer, today announces the strengthening of
its management team with the promotion of Jean-Marc Bothy to Chief
Strategy Officer and the appointment of Soumya Chandramouli as
Chief Financial Officer.
As Chief Strategy Officer
Jean-Marc will be primarily responsible for the Company's key
partnerships, which are an essential part of the Company's
strategy. The role will also encompass review of further growth
expansion opportunities. With support from Soumya, Jean-Marc will
retain the investor relations and corporate communications
functions as part of his role.
Soumya Chandramouli joined IBA
from EY in 2004 and, over this period, she has taken on increasing
responsibility within IBA's finance department, most recently as VP
Finance for the Proton Therapy and Other Accelerators division. She
holds a Master in Business from the University of Liège and a
degree from the Belgian Association of Financial Analysts
(ABAF).
Olivier Legrain,
Chief Executive Officer of IBA commented: "The
proton therapy market is growing at an unprecedented rate as the
support for the technology grows, costs come down and clinicians
recognise the importance of this treatment modality. IBA is at the
centre of this growth and with record backlogs and workforce
expansion, these management team appointments further bolster our
ability to capitalise on the many exciting opportunities facing the
Company and further establish our leadership of this
market.
"Jean-Marc has
been with IBA for more than 15 years and I am extremely pleased
that he will now focus his time on continuing to execute on the
Company's strategic direction. Similarly, after 12 years with us,
Soumya is a great addition to the management team and I look
forward to working with her more closely in her new role."
Ends
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology
company focused on bringing integrated and innovative solutions for
the diagnosis and treatment of cancer. The Company is the worldwide
technology leader in the field of proton therapy, the most advanced
form of radiation therapy available today. IBA's proton therapy
solutions are flexible and adaptable, allowing customers to choose
from universal full scale proton therapy centers as well as
compact, single room systems. In addition, IBA also has a radiation
dosimetry business and develops particle accelerators for the
medical world and industry.
Headquartered in Belgium and
employing about 1,300 people worldwide, IBA has installed systems
across the world, from Europe and the US and to the emerging
markets. IBA is listed on the pan-European stock exchange EURONEXT.
(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information
can be found at: www.iba-worldwide.com
For further information please
contact:
IBA
Jean-Marc Bothy
Chief Strategy Officer
+32 10 475 890
Investorrelations@iba-group.com
Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
Communication@iba-group.com |
For media and investor
enquiries:
Consilium Strategic Communications
Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
IBA@consilium-comms.com
Rx Communications Group (US)
Melody Carey
+1 917 322 2571
mcarey@RxIR.com
|
IBA-PR-CSO-CFO-20160602_EN
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: IBA SA via Globenewswire
HUG#2017348
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024